Zymeworks Begins Trial for Promising Cancer Therapy
Company Announcements

Zymeworks Begins Trial for Promising Cancer Therapy

Story Highlights
  • Zymeworks starts a Phase 1 trial for ZW171, targeting mesothelin-expressing cancers.
  • The trial evaluates safety and tolerability, with strong preclinical anti-tumor results.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Zymeworks (ZYME) has released an update.

Zymeworks has announced the dosing of the first patient in a Phase 1 trial for its investigational therapy ZW171, targeting advanced cancers with mesothelin expression. The trial aims to evaluate the safety and tolerability of ZW171 in ovarian and non-small cell lung cancers, with promising preclinical results showing strong anti-tumor activity.

For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyJPMorgan, Five Below downgraded: Wall Street’s top analyst calls
TheFlyZymeworks upgraded to Outperform from Market Perform at Leerink
TipRanks Canadian Auto-Generated NewsdeskZymeworks Launches Phase 1 Trial for ZW191
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App